Simplify Logo

Full-Time

Principal Scientist

Oncology

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

Biotechnology
Healthcare

Compensation Overview

$141.6k - $177kAnnually

+ Equity + Annual Bonus + RRSP Contribution + Active Lifestyle Allowance + Vacation + Professional Development Opportunities + Health Benefits

Expert

Vancouver, BC, Canada

Category
Lab & Research
Life Sciences
Medical Research
Requirements
  • 10+ years of hands-on experience in oncology, immuno-oncology, and biologics drug development
  • PhD in Pharmacology, Immunology, or related field, plus 10+ years of experience in a biopharmaceutical industry setting; if you have a MSc and 15 years of relevant experience, you will also be considered
  • Proven interpersonal skills and create value on cross-functional teams
  • Genuinely curious, with an interest in discussing innovative ideas in a highly collaborative and fast paced environment
  • Good at communicating scientific and/or technical concepts with an emphasis on application
  • Able to independently identify project needs and follow that up with constructing and implementing solutions
  • Enjoy the teamwork that comes with working on complicated biological questions and building data sets that help to predict the success of therapies
Responsibilities
  • Leading internal preclinical *in vivo* oncology models to support oncology programs
  • Designing, supporting, and interpreting pharmacology studies to generate *in vivo* proof-of-concept and build confidence in selection of molecules for clinical development
  • Collaborating with *in vitro* biology, protein engineering, and pharmacokinetics scientists, as well as external CROs and collaborators, to execute efficient PK/PD studies to identify lead molecules and advance programs to human trials
  • Mentoring team members in laboratory techniques related to tumour xenograft models
  • Reporting findings to internal program teams and partners to support data-driven decisions
  • Evaluating available preclinical and clinical data sets to build testable biological hypotheses for oncology targets and then preclinically assessing those hypotheses
  • Developing and overseeing supporting assays to assess target modulation and downstream effects at the cellular, protein, and gene level

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera focuses on challenging targets that traditional methods struggle to address. The company aims to accelerate the development of new medicines through collaborations, generating revenue from discovery services, licensing agreements, and its own therapeutic programs.

Company Stage

Series A

Total Funding

$393.1M

Headquarters

Vancouver, Canada

Founded

2012

Growth & Insights
Headcount

6 month growth

4%

1 year growth

1%

2 year growth

33%
Simplify Jobs

Simplify's Take

What believers are saying

  • Strategic collaborations with firms like Viking Global Investors and Biogen expand AbCellera's capabilities and market opportunities.
  • AbCellera's participation in high-profile industry conferences and presentations, such as AACR, showcases its cutting-edge research and strengthens its industry reputation.
  • The company's internal pipeline of therapeutic programs offers potential for significant breakthroughs and new treatments.

What critics are saying

  • The highly competitive and rapidly evolving biopharmaceutical market requires continuous innovation to maintain a competitive edge.
  • The recent resignation of board member Peter Thiel could lead to strategic and governance challenges.

What makes AbCellera Biologics unique

  • AbCellera's proprietary technology platform accelerates antibody discovery, making it faster and more efficient than traditional methods.
  • The company's ability to tackle challenging targets that have been difficult to address with traditional methods sets it apart in the biopharmaceutical market.
  • AbCellera's collaborative business model, which includes partnerships with leading investment firms and biotech companies, enhances its innovation and market reach.